Neurology · Parkinson's DiseaseRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

ACADIA Pharmaceuticals2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:31:47 PM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental NDA for NUPLAZID is a significant regulatory milestone that could strengthen ACADIA's competitive position in the Parkinson's disease market. This development necessitates close monitoring of the FDA's review timeline and potential market reactions from competitors. Regulatory context from FDA (FDA AP — NUPLAZID (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this supplemental NDA on market dynamics and competitive positioning. The strongest clinical anchor is A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (ClinicalTrials.gov), sponsor/company relevance (roche). In Neurology · Parkinson's Disease, 7 regulatory and 2 competitive items passed relevance filtering for ACADIA Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir. This acceptance may enhance ACADIA's position in the Parkinson's disease treatment market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — NUPLAZID (SUPPL) (FDA). Entity match (nuplazid); Regulatory pathway relevance (nda). The acceptance of the supplemental NDA indicates a priority review, which could expedite approval timelines and affect compliance strategies for other companies in the same therapeutic area.

Key Risks

Elevated high regulatory exposure for ACADIA Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Clinical risk from ClinicalTrials.gov (Proprioceptive Exercise in Parkinson's Disease) could weigh on ACADIA Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If approved, NUPLAZID could capture additional market share in the Parkinson's disease treatment landscape, influencing revenue projections for ACADIA and its competitors.
Portfolio teams should assess the implications of this supplemental NDA on market dynamics and competitive positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's decision on the supplemental NDA and any subsequent market reactions.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — NUPLAZID (SUPPL)
FDAhigh relevance
Entity match (nuplazid); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Regulatory pathway relevance (supplement)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of COVID-19 Treatment Authorized for Emergency Use
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Proprioceptive Exercise in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aquatic High-Intensity Interval Training for Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Bottle PEP Exercise on Expiratory Muscle Thickness, Strength, and Balance Parameters in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Probing Gut-Brain Communication in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ACADIA Pharmaceuticals
NUPLAZID
Parkinson's disease treatment market

Commercial impact

medium

If approved, NUPLAZID could capture additional market share in the Parkinson's disease treatment landscape, influencing revenue projections for ACADIA and its competitors.

Regulatory impact

high

The acceptance of the supplemental NDA indicates a priority review, which could expedite approval timelines and affect compliance strategies for other companies in the same therapeutic area.

What to watch

Monitor the timeline for the FDA's decision on the supplemental NDA and any subsequent market reactions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.